5 Questions with Eric A. Stahlberg, PhD, Director Bioinformatics and Data Science, Frederick National Laboratory for Cancer Research

Published on :

Dr. Eric Stahlberg is director of Biomedical Informatics and Data Science at the Frederick National Laboratory for Cancer Research (FNL). Stahlberg has been instrumental in establishing FNL’s high-performance computing initiative and in assembling scientific teams across multiple, complex organizations to advance predictive oncology.

Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal Officer

Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry.
Published on :

Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer. Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry.

5 Questions with Kayla Valdes, Ph.D. Senior Manager, Horizon Therapeutics

Published on :

Dr. Kayla Valdes is a Senior Manager at Horizon Therapeutics, a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare diseases. Prior to joining Horizon, Dr. Valdes worked at the National Institutes of Health as a Senior Program Manager on the Cure Sickle Cell Initiative. She was also the Associate Director of Scientific Programs at the Drug Information Association (DIA), where she developed DIA’s global content strategy by providing scientific expertise in therapeutic drug development and regulatory policy.

Luke Thorstenson Appointed Director of Business Development for Orgenesis Inc.

Published on :

Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, has appointed Luke Thorstenson as Director of Business Development. As Director of Business Development, his core responsibilities include setting the strategy for major Cell and Gene Therapy (CGT) initiatives and implementing the Orgenesis point-of-care platform in the United States. In addition, he will identify global opportunities for growth and analyze the development of value creation units and business units. He will also manage and establish new partnerships with research institutions like Johns Hopkins University, including the launch of several CGT specific facilities here in Baltimore

5 Questions with Nur A. Hasan, Ph.D., MBA, CEO of EzBiome Inc.

Published on :

Dr. Hasan is a molecular microbiologist specialized in genomics, microbiome R&D, and strategic development of technology innovation in the biotech and life science industries. His work has resulted in multiple patents and hundreds of peer-reviewed articles, abstracts, and conference proceedings in the field of microbial genomics, microbiome, molecular ecology, and infectious diseases.

BioHealth Innovation Adds Diane Ignar, Ph.D. and Dr. Loleta Robinson as NIH New Entrepreneurs-in-Residence

Published on :

BioHealth Innovation Inc. (BHI) announces the addition of Diane Ignar, Ph.D., and Dr. Loleta Robinson to the expanding Entrepreneurs-in-Residence (EIR) team. The Entrepreneur-in-Residence Program at BHI ensures that disruptive technologies receive all the resources required to transform the technology from a discovery into a commercially relevant product and eventually have a measurable impact on human health. The program was created to support scientists, early-stage startups, and licensed technologies to provide them with access to these resources. Diane will work with NIH’s National Institute on Aging, and Loleta will work with their Office of Extramural Research.

5 Questions with Jacque Myers, Healthcare and Life Sciences Lead, Slalom, LLC.

Published on :

Jacque Myers has 15 years of experience working across the health ecosystem, specializing in evidence-based communications to promote healthy behaviors and advance large-scale business transformations. She has focused on digital health acceleration for the last six years, including connected health, workflow automation, and research dissemination and implementation.

Q&A: JLL’s Pete Briskman on Montgomery County’s Life Science Market – Commercial Observer

Published on :

With the highest concentration of Ph.D.s in the country — plus proximity to the government, top-tier medical universities and numerous biomedical companies — the life sciences sector in Montgomery County is ripe to accelerate in the coming years.
There’s also a rising interest among building owners in converting assets to lab, research and biotech space throughout the D.C. region.
SEE ALSO: Investor Blackwells Comes Out Against Sam Zell’s Acquisition of Monmouth
Pete Briskman, JLL’s executive managing director and co-lead for the firm’s mid-Atlantic life sciences practice, spoke with Commercial Observer about why the area is so popular and his belief that demand will continue in the months and years ahead.
Commercial Observer: How would you portray Montgomery County’s life sciences business as we stand here in the first week of August?